Significant hypotension following buccal midazolam administration. 2010

Maria Kensche, and Josemir W Sander, and Sanjay M Sisodiya
Institute of Neurology, University College London, London, UK. maria.kensche@charite.de

Buccal midazolam is a rescue medication to reduce the duration of or stop an epileptic seizure, and is used to prevent status epilepticus. It is available in various forms, including a buccal preparation with a strength of 10 mg/1 ml. Midazolam is a licensed medication, but the buccal formulation is currently used off-licence. The prescriber takes ultimate responsibility for its use in this way. Administered by a trained person, it is receiving widespread acceptance as an alternative and effective treatment to rectally-administered diazepam in the community. The commonest side effects of midazolam are drowsiness and somnolence, although respiratory depression and paradoxical reactions, for example, agitation, restlessness and disorientation, may also occur. Hypotension is said to be a rare side effect, but with no reported cases in people administered buccal midazolam. The authors report a case of significant hypotension associated with administration of buccal midazolam for seizure management.

UI MeSH Term Description Entries
D007022 Hypotension Abnormally low BLOOD PRESSURE that can result in inadequate blood flow to the brain and other vital organs. Common symptom is DIZZINESS but greater negative impacts on the body occur when there is prolonged depravation of oxygen and nutrients. Blood Pressure, Low,Hypotension, Vascular,Low Blood Pressure,Vascular Hypotension
D008297 Male Males
D008874 Midazolam A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH. Dormicum,Midazolam Hydrochloride,Midazolam Maleate,Ro 21-3981,Versed,Hydrochloride, Midazolam,Maleate, Midazolam,Ro 21 3981,Ro 213981
D004827 Epilepsy A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313) Aura,Awakening Epilepsy,Seizure Disorder,Epilepsy, Cryptogenic,Auras,Cryptogenic Epilepsies,Cryptogenic Epilepsy,Epilepsies,Epilepsies, Cryptogenic,Epilepsy, Awakening,Seizure Disorders
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000278 Administration, Buccal Administration of a soluble dosage form between the cheek and gingiva. It may involve direct application of a drug onto the buccal mucosa, as by painting or spraying. Buccal Drug Administration,Drug Administration, Buccal,Buccal Administration,Administration, Buccal Drug,Administrations, Buccal,Administrations, Buccal Drug,Buccal Administrations,Buccal Drug Administrations,Drug Administrations, Buccal
D012720 Severity of Illness Index Levels within a diagnostic group which are established by various measurement criteria applied to the seriousness of a patient's disorder. Illness Index Severities,Illness Index Severity
D055815 Young Adult A person between 19 and 24 years of age. Adult, Young,Adults, Young,Young Adults
D018757 GABA Modulators Substances that do not act as agonists or antagonists but do affect the GAMMA-AMINOBUTYRIC ACID receptor-ionophore complex. GABA-A receptors (RECEPTORS, GABA-A) appear to have at least three allosteric sites at which modulators act: a site at which BENZODIAZEPINES act by increasing the opening frequency of GAMMA-AMINOBUTYRIC ACID-activated chloride channels; a site at which BARBITURATES act to prolong the duration of channel opening; and a site at which some steroids may act. GENERAL ANESTHETICS probably act at least partly by potentiating GABAergic responses, but they are not included here. gamma-Aminobutyric Acid Modulators,GABAergic Modulators,Acid Modulators, gamma-Aminobutyric,Modulators, GABA,Modulators, GABAergic,Modulators, gamma-Aminobutyric Acid,gamma Aminobutyric Acid Modulators

Related Publications

Maria Kensche, and Josemir W Sander, and Sanjay M Sisodiya
September 1998, British journal of clinical pharmacology,
Maria Kensche, and Josemir W Sander, and Sanjay M Sisodiya
January 2018, American journal of veterinary research,
Maria Kensche, and Josemir W Sander, and Sanjay M Sisodiya
October 1988, Anaesthesia,
Maria Kensche, and Josemir W Sander, and Sanjay M Sisodiya
April 2021, Journal of clinical pharmacology,
Maria Kensche, and Josemir W Sander, and Sanjay M Sisodiya
May 1987, Anaesthesia,
Maria Kensche, and Josemir W Sander, and Sanjay M Sisodiya
January 2005, Lancet (London, England),
Maria Kensche, and Josemir W Sander, and Sanjay M Sisodiya
May 1991, Pharmaceutical research,
Maria Kensche, and Josemir W Sander, and Sanjay M Sisodiya
March 2021, Progress in biomaterials,
Maria Kensche, and Josemir W Sander, and Sanjay M Sisodiya
March 2013, Indian pediatrics,
Maria Kensche, and Josemir W Sander, and Sanjay M Sisodiya
June 1989, Der Anaesthesist,
Copied contents to your clipboard!